Parkinson’s disease (PD) is a neurodegenerative disorder which can only be diagnosed after symptoms have appeared. At that point, 50-60 per cent of the nerve cells are already damaged.
The available drugs only target the motor symptoms and no treatment strategies that halt disease progression are available.
Dysfunctions of the protein DJ-1 are a rare cause of a specific form of Parkinson’s disease.
Therefore, understanding the protein’s function in the brain might lead to the establishment of the protein as a biomarker for early disease diagnosis and enable new treatment strategies.
In a new thesis, doctoral fellow Dominik Piston has analysed the function of DJ-1.
Specifically, he identified which other proteins interact with DJ-1 under stress conditions and a potential functional mechanism for DJ-1 which might explains the functional role this protein fulfils inside the cell.
This mechanism includes the regulation of the production of a lot of other proteins when the oxidative stress gets too high. When DJ-1 is mutated this mechanism does not work, which might cause the disease.
Understanding the function of this protein might result in the establishment of DJ-1 as a biomarker for early disease diagnosis. Potentially, it could also result in the development of new treatment strategies for Parkinson’s disease patients.
Piston defended his doctoral thesis at University of Stavanger on November 20. His thesis is titled «Interaction partners and oxidation dependent complex formation of the Parkinson’s disease associated protein DJ-1».
Piston's doctoral studies have been carried out as part of a cooperation between Centre for organelle research (CORE) at UiS, and Norway's National centre for competency on movement disorders. The project received financial support from Helse Vest, a public health organisation in Western Norway.
Piston was supervised by Professor Simon Møller at the programme at UiS. His previous studies include a Master’s degree at Philipps University Marburg.
During his doctoral project he spent one year at the Institute of Neurology, University College London, working in the laboratory of Professor Anthony Schapira, one of the world’s leading scientists in the field of neurodegenerative diseases.